Matej Vrabec1, Sofie Van Cauter2, Uwe Himmelreich3, Stefaan W. Van Gool2, Stefan Sunaert2, Steven De Vleeschouwer2, Duan uput4, Philippe Demaerel2
1Department of Radiology, University Clinical Center Ljubljana, Ljubljana, Slovenia; 2University Hospitals of Leuven, Leuven, Belgium; 3Catholic University Leuven; 4Faculty of Medicine, University of Ljubljana, Slovenia
The potential value of MR-PWI and MR-DWI to differentiate immune therapy induced inflammatory response from recurrent glioblastoma tumour growth was asessed. Both entities can present as contrast-enhancing lesions on conventional MRI. 32 follow-up MRI examinations of patients with recurrent glioblastoma (mean follow-up time 21 months) in 8 patients were analyzed for this study. Maximum lesional rCBV ratios and minimum ADC values in the contrast-enhancing area were found to be potential radiological markers to differentiate between immune therapy induced inflammatory response and recurrent glioblastoma tumour growth in glioblastoma patients treated with immune therapy.